Last reviewed · How we verify
Anticoagulant Citrate Dextrose A ACD-A (ACD-A)
At a glance
| Generic name | ACD-A |
|---|---|
| Also known as | Anticoagulant Citrate Dextrose Solution--Formula A |
| Sponsor | Arteriocyte Medical Systems, Inc. |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1) (PHASE3)
- Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2) (PHASE3)
- Genomic of CONgenital Sideroblastic Anemias (NA)
- Expanded Access for Inhaled Isoflurane Delivered Via the Sedaconda ACD-S for Sedation of Difficult-to-Sedate Adult Mechanically Ventilated Intensive Care Unit Patients
- Effect of a Reducose®-Based Supplement on Metabolic Health in Subjects With Metabolic Syndrome (NA)
- Inhaled Sedation in Critically Ill Patients (PHASE4)
- The Effect of Natural Carbonated Mineral Water Consumption on Gastrointestinal Transit and Gut Microbiota - A Randomized Controlled Trial (NA)
- CHILD (Child Health and Infection With Low Density) Malaria (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: